Badar, T., Foran, J. M., Bewersdorf, J. P., Wang, Y.-H., Coltoff, A., El Kettani, M., … Patel, A. A. (2025). Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol, 207(2), 683–686. https://doi.org/10.1111/bjh.20187

Badar, Talha, James M. Foran, Jan Philipp Bewersdorf, Yu-Hung Wang, Alexander Coltoff, Mobachir El Kettani, Kashish Shah, et al. “Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.” Br J Haematol 207, no. 2 (August 2025): 683–86. https://doi.org/10.1111/bjh.20187.

Badar T, Foran JM, Bewersdorf JP, Wang Y-H, Coltoff A, El Kettani M, et al. Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol. 2025 Aug;207(2):683–6.

Badar, Talha, et al. “Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.” Br J Haematol, vol. 207, no. 2, Aug. 2025, pp. 683–86. Pubmed, doi:10.1111/bjh.20187.

Badar T, Foran JM, Bewersdorf JP, Wang Y-H, Coltoff A, El Kettani M, Shah K, Denis Oliva F, Lin C, Jamy O, Diebold K, Shallis RM, Siddon A, Katkov D, Schoen A, Khan I, Foucar CE, Atallah E, Goldberg AD, Patel AA. Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol. 2025 Aug;207(2):683–686.